Ponatinib-induced symmetric dermatitis
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) which is used as a chemotherapeutic agent in the treatment of chronic myeloid leukemia. Despite being relatively less toxic than other older TKIs, it still has various adverse effects including skin rash. Cutaneous manifestations have v...
Main Authors: | Naman Lohani, Gayathri Rajesh, Anuradha Priyadarshini, Murugan Sundaram |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
Series: | Indian Journal of Drugs in Dermatology |
Subjects: | |
Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2022;volume=8;issue=2;spage=83;epage=85;aulast=Lohani |
Similar Items
-
Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis,
by: Jun Zhao, et al.
Published: (2020-02-01) -
Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients
by: Min Chen, et al.
Published: (2023-03-01) -
Dupilumab-induced Acute Generalized Exanthematous Pustulosis in a 17-year-old Female Chinese Patient with Atopic Dermatitis
by: LiMing Wu, et al.
Published: (2022-06-01) -
Panitumumab-Induced Periorbital Dermatitis: A Case Report
by: Pongbangpho N, et al.
Published: (2024-04-01) -
Pharmacovigilance in Geriatric Patient- A Prospective Observational Study done in a Tertiary Care Hospital of Odisha, India
by: Satyabrata Sahoo, et al.
Published: (2022-01-01)